Albert (Gus) Davis, MD, PhD

Instructor in Neurology

Phone: 314-362-6908

Related Links


  • 2002, Bachelor of Science: Emory University, Atlanta, GA
  • 2009, PhD: Emory University, Atlanta, GA
  • 2011, MD: Vanderbilt University, Nashville, TN
  • 2015, Residency: Washington University, St. Louis, MO

Board Certifications

  • Neurology


  • Alpha Omega Alpha (2015)
  • Paul Calabresi / Pharmaceutical Research and Manufacturers Association Foundation Clinical Pharmacology Medical Student Fellowship (2005)
  • Ruth L. Kirschstein National Research Service Award Predoctoral Fellowship (2007)
  • American Brain Foundation / American Academy of Neurology Clinical Research Training Fellowship (2015)
  • Foundation Postdoctoral Fellowship (2015)

Clinical Interests

Dr. Davis sees patients with Parkinson Disease and related disorders at the Movement Disorders Center.

Research Interests

Dr. Davis’ laboratory research is aimed at understanding the molecular and cellular mechanisms of protein aggregation and neurodegeneration in Parkinson Disease, with a special interest in factors that contribute to dementia in Parkinson Disease and related disorders including Dementia with Lewy Bodies.


  1. Wang MS, Fang G, Culver DG, Davis AA, Rich MM, Glass JD (2001) The WldS protein protects against axonal degeneration: a model of gene therapy for peripheral neuropathy. Ann Neurol. Dec;50(6):773-9.
  2. Wang MS, Davis AA, Culver DG, Glass JD (2002) WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol. Oct;52(4):442-7.
  3. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. Feb;185(2):232-40.
  4. Wang MS, Davis AA, Culver DG, Wang Q, Powers JC, Glass JD (2004) Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain. Mar;127(Pt 3):671-9. Epub 2004 Feb 4.
  5. Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, Coleman M, Asress S, Alexander GM, Glass JD (2005) The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis. Jun-Jul;19(1-2):293-300.
  6. Jones C, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, Bradley SR, Peterson TE, Ansari MS, Baldwin RM, Kessler RM, Deutch AY, Lah JJ, Levey AI, Lindsley CW, Conn PJ (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci. Oct 8;28(41):10422-33.
  7. Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, Jadhav SB, Menon UN, Xiang Z, Watson ML, Christian EP, Doherty JJ, Quirk MC, Snyder DH, Lah JJ, Levey AI, Nicolle MM, Lindsley CW, Conn PJ (2009) A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci. Nov 11;29(45):14271-14286.
  8. Jeon J, Dencker D, Wörtwein G, Woldbye D, Cui Y, Davis AA, Levey AI, Schütz G, Sager T, Mørk A, Li C, Deng C-X, Fink-Jensen A, and Wess J (2010) A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors. J Neurosci. Feb 10;30(6): 2396-2405.
  9. Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI (2010) Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci. Mar 24;30(12):4190-4196.
  10. Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, Hanson BJ, Lindsley CW, Conn PJ, Lah JJ, Levey AI (2010) Differential effects of M1 muscarinic acetylcholine receptor allosteric agonists on receptor activation, arrestin-3 recruitment, and receptor downregulation. ACS Chem Neurosci Aug 18; 1(8):542-551.
  11. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE, Lebois EP, Xiang Z, Sheffler DJ, Cho HP, Davis AA, Nemirovsky NE, Mennenga SE, Camp BW, Bimonte-Nelson HA, Bode J, Italiano K, Morrison R, Daniels JS, Niswender CM, Olive MF, Lindsley CW, Jones CK, Conn PJ (2012) Novel Allosteric Agonists of M1 Muscarinic Acetylcholine Receptors Induce Brain Region-Specific Responses that Correspond with Behavioral Effects in Animal Models. J Neurosci. Jun 20; 32(25):8532-8544.
  12. Davis AA, Andruska KM, Benitez BA, Racette BA, Perlmutter JS, Cruchaga C (2016) Variants in GBA, SNCA, and MAPT Influence Parkinson Disease Risk, Age at Onset, and Progression. Neurobiology of Aging Jan; 37:209.e1-209.e7
  13. Benitez BA, Davis AA, Jin SC, Ibanez L, Ortega-Cubero S, Pastor P, Choi J, Cooper B, Perlmutter JS, Singleton AB, Cruchaga C (2016) Resequence analysis of the Medelian and GWAS genes in Parkinson disease. Molecular Neurodegeneration Apr 19;11:29
  14. Davis AA and Racette BA (2016). Parkinson Disease and Cognitive Impairment: Five new things. Neurology Clinical Practice Oct; 6(5):452-458.